Collaboration will enable rapid advancement of a joint preclinical proof of concept program for type 1 diabetes
Galvus has the potential to contribute significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of Rs. 268 crore
Pre-filled pens containing a combination of insulin glargine 100 Units/mL and lixisenatide for once-daily dosing
MindRank expects to initiate a Phase I safety study in the first quarter of 2023.
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
As per 10th edition of International Diabetes Federation (IDF) Atlas, 2021, India has 74.2 million people with diabetes between the age of 20-79 years
Through lifestyle modifications, ADORE will assess the progress of patients based on parameters like reduction in blood sugar levels and weight, among others
India is home to nearly 80 million diabetics and this number is expected to rise to a staggering 134 million in the next 25 years.
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Subscribe To Our Newsletter & Stay Updated
